Il-15-based fusions to il-7 and il-21
US-2022033455-A1 · Feb 3, 2022 · US
US12410224B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12410224-B2 |
| Application number | US-202318472053-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 21, 2023 |
| Priority date | Aug 28, 2017 |
| Publication date | Sep 9, 2025 |
| Grant date | Sep 9, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
Opening claim text (preview).
What is claimed is: 1. A soluble fusion protein complex comprising: a first fusion protein comprising interleukin-21 (IL-21) (SEQ ID NO: 6) and interleukin-15 receptor alpha sushi-binding domain/Fc (IL-15RαSu/Fc) (SEQ ID NO:8); and a second fusion protein comprising interleukin-7 (IL-7) (SEQ ID NO:10) and an IL-15 variant comprising an N72D mutation (IL-15N72D) (SEQ ID NO:12) or human wild-type IL-15, wherein the first and second fusion proteins are non-covalently linked to form the soluble fusion protein complex. 2. The soluble fusion protein complex of claim 1 , wherein the IL-21 is attached to the N-terminus of the IL-15RαSu/Fc. 3. The soluble fusion protein complex of claim 1 , wherein the IL-21 is attached to the C-terminus of the IL-15RαSu/Fc. 4. The soluble fusion protein complex of claim 2 , wherein the IL-7 is attached to the N-terminus of the IL-15N72D or the human wild-type IL 15. 5. The soluble fusion protein complex of claim 2 , wherein the IL-7 is attached to the C-terminus of the IL-15N72D or the human wild-type IL-15. 6. The soluble fusion protein complex of claim 3 , wherein the IL-7 is attached to the N-terminus of the IL-15N72D or the human wild-type IL-15. 7. The soluble fusion protein complex of claim 3 , wherein the IL-7 is attached to the C-terminus of the IL-15N72D or the human wild-type IL-15. 8. The soluble fusion protein complex of claim 1 , wherein the soluble fusion protein complex is covalently linked to a second soluble fusion protein complex by a disulfide bond linking the Fc domain of the first soluble fusion protein complex to an Fc domain of the second soluble fusion protein complex, wherein the second soluble fusion protein complex is identical to the first soluble fusion protein complex.
Glucan 1,4-alpha-maltotetraohydrolase (3.2.1.60) · CPC title
Amylo-alpha-1,6-glucosidase (3.2.1.33) · CPC title
Beta-amylase (3.2.1.2) · CPC title
for yeasts · CPC title
with yeasts · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.